Neuropharmacological Treatment of Mental Dysfunction in Parkinson’s Disease

Many patients with Parkinson's Disease (PD) experience significant cognitive and mood impairment -even early in the course of the disease. These mental impairments are only partially responsive to levodopa treatment and are often as disabling as the motor impairment, particularly in mid and lat...

Full description

Bibliographic Details
Main Authors: Patrick McNamara, Raymon Durso
Format: Article
Language:English
Published: Hindawi Limited 2006-01-01
Series:Behavioural Neurology
Online Access:http://dx.doi.org/10.1155/2006/138263
id doaj-15c03fc259c14b908589a661e1e2244f
record_format Article
spelling doaj-15c03fc259c14b908589a661e1e2244f2021-07-02T08:15:39ZengHindawi LimitedBehavioural Neurology0953-41801875-85842006-01-01171435110.1155/2006/138263Neuropharmacological Treatment of Mental Dysfunction in Parkinson’s DiseasePatrick McNamara0Raymon Durso1Department of Neurology, Boston University School of Medicine, Boston VA Healthcare System, Boston, MA, USADepartment of Neurology, Boston University School of Medicine, Boston VA Healthcare System, Boston, MA, USAMany patients with Parkinson's Disease (PD) experience significant cognitive and mood impairment -even early in the course of the disease. These mental impairments are only partially responsive to levodopa treatment and are often as disabling as the motor impairment, particularly in mid and late stages of the disease. Investigators have recently begun a search for new agents that can effectively treat mental dysfunction of PD. Although there have been only a handful of properly controlled clinical trials of interventions targeted at amelioration of mental dysfunction in PD, progress has been made. Based on the available evidence, targeting catecholaminergic and cholinergic function may be an effective strategy for amelioration of cognitve, mood and psychiatric disturbances in PD.http://dx.doi.org/10.1155/2006/138263
collection DOAJ
language English
format Article
sources DOAJ
author Patrick McNamara
Raymon Durso
spellingShingle Patrick McNamara
Raymon Durso
Neuropharmacological Treatment of Mental Dysfunction in Parkinson’s Disease
Behavioural Neurology
author_facet Patrick McNamara
Raymon Durso
author_sort Patrick McNamara
title Neuropharmacological Treatment of Mental Dysfunction in Parkinson’s Disease
title_short Neuropharmacological Treatment of Mental Dysfunction in Parkinson’s Disease
title_full Neuropharmacological Treatment of Mental Dysfunction in Parkinson’s Disease
title_fullStr Neuropharmacological Treatment of Mental Dysfunction in Parkinson’s Disease
title_full_unstemmed Neuropharmacological Treatment of Mental Dysfunction in Parkinson’s Disease
title_sort neuropharmacological treatment of mental dysfunction in parkinson’s disease
publisher Hindawi Limited
series Behavioural Neurology
issn 0953-4180
1875-8584
publishDate 2006-01-01
description Many patients with Parkinson's Disease (PD) experience significant cognitive and mood impairment -even early in the course of the disease. These mental impairments are only partially responsive to levodopa treatment and are often as disabling as the motor impairment, particularly in mid and late stages of the disease. Investigators have recently begun a search for new agents that can effectively treat mental dysfunction of PD. Although there have been only a handful of properly controlled clinical trials of interventions targeted at amelioration of mental dysfunction in PD, progress has been made. Based on the available evidence, targeting catecholaminergic and cholinergic function may be an effective strategy for amelioration of cognitve, mood and psychiatric disturbances in PD.
url http://dx.doi.org/10.1155/2006/138263
work_keys_str_mv AT patrickmcnamara neuropharmacologicaltreatmentofmentaldysfunctioninparkinsonsdisease
AT raymondurso neuropharmacologicaltreatmentofmentaldysfunctioninparkinsonsdisease
_version_ 1721334907666432000